Evidence map›Paper›PMID 24731660›Full record

ReviewThe lancet. Diabetes & endocrinology2014

Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.

Rita Rastogi Kalyani, Mark Corriere, Luigi Ferrucci

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Diabetes & endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 570 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
570citing papers in PubMed, 7 pooled it
28.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02297997 early_phase1completednot on this map

Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study

TypeinterventionalSponsorSeoul National University HospitalRan2014 to 2015Enrolled65ConditionsSarcopeniaArmscetylpyridinium chloride, Placebo
NCT02575235 early_phase1completednot on this mapstarted 2015, after this paper: background citation

Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia

TypeinterventionalSponsorSeoul National University HospitalRan2015 to 2016Enrolled100ConditionsSarcopeniaArmsCetylpyridinium Chloride (CPC), placebo
3 · Its place in the literature

Who cites it

570 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,079 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

510 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rita Rastogi KalyaniDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
Mark CorriereDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
Luigi FerrucciClinical Research Branch, National Institute on Aging, Baltimore, MD, USA. Electronic address: ferruccilu@mail.nih.gov.
Johns Hopkins University · USNational Institute on Aging · US

Funding

The Baltimore Longitudinal Study Of AgingZIAAG000015 · NIA · NATIONAL INSTITUTE ON AGING · PI SIMONSICK, ELEANOR MARIE · 2009 to 2025
$116.9M
Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WONDISFORD, FREDRIC E. · 2013 to 2017
$9.7M
Clinical Research&Epidemiology in Diabetes&EndocrinologyT32DK062707 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Wendy Lynet Bennett · 2002 to 2026
$7.3M
Glucose Insulin and Muscle LossK23DK093583 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI KALYANI, RITA R · 2012 to 2015
$635k
Intramural NIH HHS ZIA AG000015NIA NIH HHS P30 AG021334NIA NIH HHS P30-AG021334NIDDK NIH HHS K23 DK093583NIDDK NIH HHS K23-DK093583NIDDK NIH HHS P30 DK079637NIDDK NIH HHS T32 DK062707NIDDK NIH HHS T32-DK062707
6 · The paper itself

Abstract

The term sarcopenia refers to the loss of muscle mass that occurs with ageing. On the basis of study results showing that muscle mass is only moderately related to functional outcomes, international working groups have proposed that loss of muscle strength or physical function should also be included in the definition. Irrespective of how sarcopenia is defined, both low muscle mass and poor muscle strength are clearly highly prevalent and important risk factors for disability and potentially mortality in individuals as they age. Many chronic diseases, in addition to ageing, could also accelerate decrease of muscle mass and strength, and this effect could be a main underlying mechanism by which chronic diseases cause physical disability. In this Review, we address both age-related and disease-related muscle loss, with a focus on diabetes and obesity but including other disease states, and potential common mechanisms and treatments. Development of treatments for age-related and disease-related muscle loss might improve active life expectancy in older people, and lead to substantial health-care savings and improved quality of life.

Indexed as

Diabetes ComplicationsEndocrine System DiseasesHumansMaleObesitySarcopenia

Identifiers

PMID24731660
PMCPMC4156923
OpenAlexW2139789661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.